• Eduard Baladia, Ana Beatriz Pizarro, Luis Ortiz-Muñoz, and Gabriel Rada.
• Red de Nutrición Basada en la Evidencia, Academia Española de Nutrición y Dietética, Pamplona, España. Email: e.baladia@academianutricion.org. Dirección: C/ Consell de Cent 314, pral B 08007, Barcelona, España. ORCID: 0000-0002-8123-8736.
• Medwave. 2020 Jul 28; 20 (6): e7978.

ObjectiveThis living systematic review aims to provide a timely, rigorous, and continuously updated summary of the available evidence on the role of vitamin C in treating patients with COVID-19.Data SourcesWe conducted searches in PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature, and in a centralized repository in L·OVE (Living OVerview of Evidence). In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it comprises and has been customized to group all COVID-19 evidence in one place. All the searches covered the period until April 29, 2020 (one day before submission).Study Selection And MethodsWe adapted an already published standard protocol for multiple parallel systematic reviews. We searched for randomized trials evaluating the effect, in patients with COVID-19, of vitamin C versus placebo or no treatment. Anticipating the lack of randomized trials directly addressing this question, we also searched for trials evaluating MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19. Two reviewers independently screened each study for eligibility. A living, web-based version of this review will be openly available during the COVID-19 pandemic, and we will resubmit it to the journal whenever there are substantial updates.ResultsWe screened 95 records, but no study was considered eligible. We identified 20 ongoing studies, including 13 randomized trials evaluating vitamin C in COVID-19.ConclusionsWe did not find any studies that met our inclusion criteria, and hence there is no evidence to support or refute the use of vitamin C in the treatment of patients with COVID-19. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon.Prospero Registration NumberCRD42020181216.

21 keywords...

hide…